Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors Hematology
Biosimilars
Global Health
Abbreviations
Tafinlar + MekinistⓇ - BRAF inhibitor and MEK inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milestone(s)
Publication
NCT02684058 (CDRB436G2201)
BRAFV600 mutant gliomas
Phase 2
142
Objective response rate
Dabrafenib + trametinib (dose based on age and weight)
Children and adolescent patients with BRAF V600 mutation positive relapsed or
refractory high grade glioma (HGG) or BRAF V600 mutation positive low grade
glioma (LGG)
Q4 2021 (actual)
TBD
125 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation